Fusion Gene Studies
in Kim Lab

FusionBase FusionGDB FusionGDB2 FusionPDB FusionNeoAntigen FusionAI FusionNW FGviewer Publication Contact
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:BCR-PDGFRA (FusionGDB2 ID:HG613TG5156)

Fusion Gene Summary for BCR-PDGFRA

check button Fusion gene summary
Fusion gene informationFusion gene name: BCR-PDGFRA
Fusion gene ID: hg613tg5156
HgeneTgene
Gene symbol

BCR

PDGFRA

Gene ID

613

5156

Gene nameBCR activator of RhoGEF and GTPaseplatelet derived growth factor receptor alpha
SynonymsALL|BCR1|CML|D22S11|D22S662|PHLCD140A|PDGFR-2|PDGFR2
Cytomap('BCR')('PDGFRA')

22q11.23

4q12

Type of geneprotein-codingprotein-coding
Descriptionbreakpoint cluster region proteinBCR, RhoGEF and GTPase activating proteinBCR/FGFR1 chimera proteinFGFR1/BCR chimera proteinbreakpoint cluster regionrenal carcinoma antigen NY-REN-26platelet-derived growth factor receptor alphaCD140 antigen-like family member ACD140a antigenPDGF-R-alphaalpha-type platelet-derived growth factor receptorplatelet-derived growth factor receptor 2platelet-derived growth factor receptor, alpha polype
Modification date2020031320200329
UniProtAcc

P11274

P16234

Ensembl transtripts involved in fusion geneENST00000436990, ENST00000305877, 
ENST00000359540, ENST00000398512, 
Fusion gene scores* DoF score22 X 142 X 16=4998418 X 27 X 8=3888
# samples 16317
** MAII scorelog2(163/49984*10)=-4.93852248902354
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(17/3888*10)=-4.51542156746808
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: BCR [Title/Abstract] AND PDGFRA [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointBCR(23652041)-PDGFRA(55141056), # samples:2
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneBCR

GO:0090630

activation of GTPase activity

7479768

TgenePDGFRA

GO:0008284

positive regulation of cell proliferation

10806482

TgenePDGFRA

GO:0010544

negative regulation of platelet activation

8188664

TgenePDGFRA

GO:0018108

peptidyl-tyrosine phosphorylation

1646396|2536956|8188664

TgenePDGFRA

GO:0030335

positive regulation of cell migration

17470632

TgenePDGFRA

GO:0034614

cellular response to reactive oxygen species

24190966

TgenePDGFRA

GO:0038091

positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway

17470632

TgenePDGFRA

GO:0046777

protein autophosphorylation

1646396|2536956|8188664

TgenePDGFRA

GO:0048008

platelet-derived growth factor receptor signaling pathway

2536956|10806482

TgenePDGFRA

GO:0048146

positive regulation of fibroblast proliferation

10806482



check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4chronic myeloproliferative disordersAY303970BCRchr22

23652041

PDGFRAchr4

55141056
ChimerKB3..BCRchr22

23615320

+PDGFRAchr4

55141007

+
ChiTaRS5.0N/AAY303970BCRchr22

23652041

+PDGFRAchr4

55141056

+


Top

Fusion Gene ORF analysis for BCR-PDGFRA

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
3UTR-3CDSENST00000436990ENST00000257290BCRchr22

23652041

PDGFRAchr4

55141056

3UTR-3CDSENST00000436990ENST00000257290BCRchr22

23652041

+PDGFRAchr4

55141056

+
3UTR-intronENST00000436990ENST00000508170BCRchr22

23652041

PDGFRAchr4

55141056

3UTR-intronENST00000436990ENST00000508170BCRchr22

23652041

+PDGFRAchr4

55141056

+
5CDS-intronENST00000305877ENST00000508170BCRchr22

23615320

+PDGFRAchr4

55141007

+
5CDS-intronENST00000359540ENST00000508170BCRchr22

23615320

+PDGFRAchr4

55141007

+
In-frameENST00000305877ENST00000257290BCRchr22

23615320

+PDGFRAchr4

55141007

+
In-frameENST00000359540ENST00000257290BCRchr22

23615320

+PDGFRAchr4

55141007

+
intron-3CDSENST00000305877ENST00000257290BCRchr22

23652041

PDGFRAchr4

55141056

intron-3CDSENST00000305877ENST00000257290BCRchr22

23652041

+PDGFRAchr4

55141056

+
intron-3CDSENST00000359540ENST00000257290BCRchr22

23652041

PDGFRAchr4

55141056

intron-3CDSENST00000359540ENST00000257290BCRchr22

23652041

+PDGFRAchr4

55141056

+
intron-3CDSENST00000398512ENST00000257290BCRchr22

23652041

PDGFRAchr4

55141056

intron-3CDSENST00000398512ENST00000257290BCRchr22

23615320

+PDGFRAchr4

55141007

+
intron-3CDSENST00000398512ENST00000257290BCRchr22

23652041

+PDGFRAchr4

55141056

+
intron-3CDSENST00000436990ENST00000257290BCRchr22

23615320

+PDGFRAchr4

55141007

+
intron-intronENST00000305877ENST00000508170BCRchr22

23652041

PDGFRAchr4

55141056

intron-intronENST00000305877ENST00000508170BCRchr22

23652041

+PDGFRAchr4

55141056

+
intron-intronENST00000359540ENST00000508170BCRchr22

23652041

PDGFRAchr4

55141056

intron-intronENST00000359540ENST00000508170BCRchr22

23652041

+PDGFRAchr4

55141056

+
intron-intronENST00000398512ENST00000508170BCRchr22

23652041

PDGFRAchr4

55141056

intron-intronENST00000398512ENST00000508170BCRchr22

23615320

+PDGFRAchr4

55141007

+
intron-intronENST00000398512ENST00000508170BCRchr22

23652041

+PDGFRAchr4

55141056

+
intron-intronENST00000436990ENST00000508170BCRchr22

23615320

+PDGFRAchr4

55141007

+

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000305877BCRchr2223615320+ENST00000257290PDGFRAchr455141007+7317272575143411196
ENST00000359540BCRchr2223615320+ENST00000257290PDGFRAchr455141007+7162257059641861196

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score

Top

Fusion Genomic Features for BCR-PDGFRA


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)


Top

Fusion Protein Features for BCR-PDGFRA


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:23652041/chr4:55141056)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
BCR

P11274

PDGFRA

P16234

FUNCTION: Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein (GAP) domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the active GTP-bound form (PubMed:7479768, PubMed:1903516, PubMed:17116687). The central Dbl homology (DH) domain functions as guanine nucleotide exchange factor (GEF) that modulates the GTPases CDC42, RHOA and RAC1. Promotes the conversion of CDC42, RHOA and RAC1 from the GDP-bound to the GTP-bound form (PubMed:7479768, PubMed:23940119). The amino terminus contains an intrinsic kinase activity (PubMed:1657398). Functions as an important negative regulator of neuronal RAC1 activity (By similarity). Regulates macrophage functions such as CSF1-directed motility and phagocytosis through the modulation of RAC1 activity (PubMed:17116687). Plays a major role as a RHOA GEF in keratinocytes being involved in focal adhesion formation and keratinocyte differentiation (PubMed:23940119). {ECO:0000250|UniProtKB:Q6PAJ1, ECO:0000269|PubMed:1657398, ECO:0000269|PubMed:17116687, ECO:0000269|PubMed:1903516, ECO:0000269|PubMed:23940119, ECO:0000269|PubMed:7479768}.FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. {ECO:0000269|PubMed:10734113, ECO:0000269|PubMed:10947961, ECO:0000269|PubMed:11297552, ECO:0000269|PubMed:12522257, ECO:0000269|PubMed:1646396, ECO:0000269|PubMed:17087943, ECO:0000269|PubMed:1709159, ECO:0000269|PubMed:17141222, ECO:0000269|PubMed:20972453, ECO:0000269|PubMed:21224473, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:2554309, ECO:0000269|PubMed:8188664, ECO:0000269|PubMed:8760137, ECO:0000269|PubMed:8943348}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

Fusion Gene Sequence for BCR-PDGFRA


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>9530_9530_1_BCR-PDGFRA_BCR_chr22_23615320_ENST00000305877_PDGFRA_chr4_55141007_ENST00000257290_length(transcript)=7317nt_BP=2725nt
TTCCAGGACTGCAGAACTGGCCCAGACCTCTGTATTGGAAAGGTCTTTATGGACCAGGGAGTCCGGTGTCTTTTTTACGGGGGACCCCTG
GGCTGCGAGTTGCACAGTCCAATTCGCTGTTGTTAGGGCCTCAGTTTCCCAAAAGGCACAGGGACGGGGGGAGGGTGGCGGCTCGATGGG
GGAGCCGCCTCCAGGGGGCCCCCCCGCCCTGTGCCCACGGCGCGGCCCCTTTAAGAGGCCCGCCTGGCTCCGTCATCCGCGCCGCGGCCA
CCTCCCCCCGGCCCTCCCCTTCCTGCGGCGCAGAGTGCGGGCCGGGCGGGAGTGCGGCGAGAGCCGGCTGGCTGAGCTTAGCGTCCGAGG
AGGCGGCGGCGGCGGCGGCGGCACGGCGGCGGCGGGGCTGTGGGGCGGTGCGGAAGCGAGAGGCGAGGAGCGCGCGGGCCGTGGCCAGAG
TCTGGCGGCGGCCTGGCGGAGCGGAGAGCAGCGCCCGCGCCTCGCCGTGCGGAGGAGCCCCGCACACAATAGCGGCGCGCGCAGCCCGCG
CCCTTCCCCCCGGCGCGCCCCGCCCCGCGCGCCGAGCGCCCCGCTCCGCCTCACCTGCCACCAGGGAGTGGGCGGGCATTGTTCGCCGCC
GCCGCCGCCGCGCGGGCCATGGGGGCCGCCCGGCGCCCGGGGCCGGGCTGGCGAGGCGCCGCGCCGCCGCTGAGACGGGCCCCGCGCGCA
GCCCGGCGGCGCAGGTAAGGCCGGCCGCGCCATGGTGGACCCGGTGGGCTTCGCGGAGGCGTGGAAGGCGCAGTTCCCGGACTCAGAGCC
CCCGCGCATGGAGCTGCGCTCAGTGGGCGACATCGAGCAGGAGCTGGAGCGCTGCAAGGCCTCCATTCGGCGCCTGGAGCAGGAGGTGAA
CCAGGAGCGCTTCCGCATGATCTACCTGCAGACGTTGCTGGCCAAGGAAAAGAAGAGCTATGACCGGCAGCGATGGGGCTTCCGGCGCGC
GGCGCAGGCCCCCGACGGCGCCTCCGAGCCCCGAGCGTCCGCGTCGCGCCCGCAGCCAGCGCCCGCCGACGGAGCCGACCCGCCGCCCGC
CGAGGAGCCCGAGGCCCGGCCCGACGGCGAGGGTTCTCCGGGTAAGGCCAGGCCCGGGACCGCCCGCAGGCCCGGGGCAGCCGCGTCGGG
GGAACGGGACGACCGGGGACCCCCCGCCAGCGTGGCGGCGCTCAGGTCCAACTTCGAGCGGATCCGCAAGGGCCATGGCCAGCCCGGGGC
GGACGCCGAGAAGCCCTTCTACGTGAACGTCGAGTTTCACCACGAGCGCGGCCTGGTGAAGGTCAACGACAAAGAGGTGTCGGACCGCAT
CAGCTCCCTGGGCAGCCAGGCCATGCAGATGGAGCGCAAAAAGTCCCAGCACGGCGCGGGCTCGAGCGTGGGGGATGCATCCAGGCCCCC
TTACCGGGGACGCTCCTCGGAGAGCAGCTGCGGCGTCGACGGCGACTACGAGGACGCCGAGTTGAACCCCCGCTTCCTGAAGGACAACCT
GATCGACGCCAATGGCGGTAGCAGGCCCCCTTGGCCGCCCCTGGAGTACCAGCCCTACCAGAGCATCTACGTCGGGGGCATGATGGAAGG
GGAGGGCAAGGGCCCGCTCCTGCGCAGCCAGAGCACCTCTGAGCAGGAGAAGCGCCTTACCTGGCCCCGCAGGTCCTACTCCCCCCGGAG
TTTTGAGGATTGCGGAGGCGGCTATACCCCGGACTGCAGCTCCAATGAGAACCTCACCTCCAGCGAGGAGGACTTCTCCTCTGGCCAGTC
CAGCCGCGTGTCCCCAAGCCCCACCACCTACCGCATGTTCCGGGACAAAAGCCGCTCTCCCTCGCAGAACTCGCAACAGTCCTTCGACAG
CAGCAGTCCCCCCACGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGGCCACCATCGTGGGCGTCCGCAAGAC
CGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAGACGCAGATGGCTCGTTCGGAACACCACCTGGATACGGCTGCGCTGC
AGACCGGGCAGAGGAGCAGCGCCGGCACCAAGATGGGCTGCCCTACATTGATGACTCGCCCTCCTCATCGCCCCACCTCAGCAGCAAGGG
CAGGGGCAGCCGGGATGCGCTGGTCTCGGGAGCCCTGGAGTCCACTAAAGCGAGTGAGCTGGACTTGGAAAAGGGCTTGGAGATGAGAAA
ATGGGTCCTGTCGGGAATCCTGGCTAGCGAGGAGACTTACCTGAGCCACCTGGAGGCACTGCTGCTGCCCATGAAGCCTTTGAAAGCCGC
TGCCACCACCTCTCAGCCGGTGCTGACGAGTCAGCAGATCGAGACCATCTTCTTCAAAGTGCCTGAGCTCTACGAGATCCACAAGGAGTT
CTATGATGGGCTCTTCCCCCGCGTGCAGCAGTGGAGCCACCAGCAGCGGGTGGGCGACCTCTTCCAGAAGCTGGCCAGCCAGCTGGGTGT
GTACCGGGCCTTCGTGGACAACTACGGAGTTGCCATGGAAATGGCTGAGAAGTGCTGTCAGGCCAATGCTCAGTTTGCAGAAATCTCCGA
GAACCTGAGAGCCAGAAGCAACAAAGATGCCAAGGATCCAACGACCAAGAACTCTCTGGAAACTCTGCTCTACAAGCCTGTGGACCGTGT
GACGAGGAGCACGCTGGTCCTCCATAAACCGAGGTATGAAATTCGCTGGAGGGTCATTGAATCAATCAGCCCAGATGGACATGAATATAT
TTATGTGGACCCGATGCAGCTGCCTTATGACTCAAGATGGGAGTTTCCAAGAGATGGACTAGTGCTTGGTCGGGTCTTGGGGTCTGGAGC
GTTTGGGAAGGTGGTTGAAGGAACAGCCTATGGATTAAGCCGGTCCCAACCTGTCATGAAAGTTGCAGTGAAGATGCTAAAACCCACGGC
CAGATCCAGTGAAAAACAAGCTCTCATGTCTGAACTGAAGATAATGACTCACCTGGGGCCACATTTGAACATTGTAAACTTGCTGGGAGC
CTGCACCAAGTCAGGCCCCATTTACATCATCACAGAGTATTGCTTCTATGGAGATTTGGTCAACTATTTGCATAAGAATAGGGATAGCTT
CCTGAGCCACCACCCAGAGAAGCCAAAGAAAGAGCTGGATATCTTTGGATTGAACCCTGCTGATGAAAGCACACGGAGCTATGTTATTTT
ATCTTTTGAAAACAATGGTGACTACATGGACATGAAGCAGGCTGATACTACACAGTATGTCCCCATGCTAGAAAGGAAAGAGGTTTCTAA
ATATTCCGACATCCAGAGATCACTCTATGATCGTCCAGCCTCATATAAGAAGAAATCTATGTTAGACTCAGAAGTCAAAAACCTCCTTTC
AGATGATAACTCAGAAGGCCTTACTTTATTGGATTTGTTGAGCTTCACCTATCAAGTTGCCCGAGGAATGGAGTTTTTGGCTTCAAAAAA
TTGTGTCCACCGTGATCTGGCTGCTCGCAACGTCCTCCTGGCACAAGGAAAAATTGTGAAGATCTGTGACTTTGGCCTGGCCAGAGACAT
CATGCATGATTCGAACTATGTGTCGAAAGGCAGTACCTTTCTGCCCGTGAAGTGGATGGCTCCTGAGAGCATCTTTGACAACCTCTACAC
CACACTGAGTGATGTCTGGTCTTATGGCATTCTGCTCTGGGAGATCTTTTCCCTTGGTGGCACCCCTTACCCCGGCATGATGGTGGATTC
TACTTTCTACAATAAGATCAAGAGTGGGTACCGGATGGCCAAGCCTGACCACGCTACCAGTGAAGTCTACGAGATCATGGTGAAATGCTG
GAACAGTGAGCCGGAGAAGAGACCCTCCTTTTACCACCTGAGTGAGATTGTGGAGAATCTGCTGCCTGGACAATATAAAAAGAGTTATGA
AAAAATTCACCTGGACTTCCTGAAGAGTGACCATCCTGCTGTGGCACGCATGCGTGTGGACTCAGACAATGCATACATTGGTGTCACCTA
CAAAAACGAGGAAGACAAGCTGAAGGACTGGGAGGGTGGTCTGGATGAGCAGAGACTGAGCGCTGACAGTGGCTACATCATTCCTCTGCC
TGACATTGACCCTGTCCCTGAGGAGGAGGACCTGGGCAAGAGGAACAGACACAGCTCGCAGACCTCTGAAGAGAGTGCCATTGAGACGGG
TTCCAGCAGTTCCACCTTCATCAAGAGAGAGGACGAGACCATTGAAGACATCGACATGATGGATGACATCGGCATAGACTCTTCAGACCT
GGTGGAAGACAGCTTCCTGTAACTGGCGGATTCGAGGGGTTCCTTCCACTTCTGGGGCCACCTCTGGATCCCGTTCAGAAAACCACTTTA
TTGCAATGCAGAGGTTGAGAGGAGGACTTGGTTGATGTTTAAAGAGAAGTTCCCAGCCAAGGGCCTCGGGGAGCGTTCTAAATATGAATG
AATGGGATATTTTGAAATGAACTTTGTCAGTGTTGCCTCTTGCAATGCCTCAGTAGCATCTCAGTGGTGTGTGAAGTTTGGAGATAGATG
GATAAGGGAATAATAGGCCACAGAAGGTGAACTTTGTGCTTCAAGGACATTGGTGAGAGTCCAACAGACACAATTTATACTGCGACAGAA
CTTCAGCATTGTAATTATGTAAATAACTCTAACCAAGGCTGTGTTTAGATTGTATTAACTATCTTCTTTGGACTTCTGAAGAGACCACTC
AATCCATCCATGTACTTCCCTCTTGAAACCTGATGTCAGCTGCTGTTGAACTTTTTAAAGAAGTGCATGAAAAACCATTTTTGAACCTTA
AAAGGTACTGGTACTATAGCATTTTGCTATCTTTTTTAGTGTTAAAGAGATAAAGAATAATAATTAACCAACCTTGTTTAATAGATTTGG
GTCATTTAGAAGCCTGACAACTCATTTTCATATTGTAATCTATGTTTATAATACTACTACTGTTATCAGTAATGCTAAATGTGTAATAAT
GTAACATGATTTCCCTCCAGAGAAAGCACAATTTAAAACAATCCTTACTAAGTAGGTGATGAGTTTGACAGTTTTTGACATTTATATTAA
ATAACATGTTTCTCTATAAAGTATGGTAATAGCTTTAGTGAATTAAATTTAGTTGAGCATAGAGAACAAAGTAAAAGTAGTGTTGTCCAG
GAAGTCAGAATTTTTAACTGTACTGAATAGGTTCCCCAATCCATCGTATTAAAAAACAATTAACTGCCCTCTGAAATAATGGGATTAGAA
ACAAACAAAACTCTTAAGTCCTAAAAGTTCTCAATGTAGAGGCATAAACCTGTGCTGAACATAACTTCTCATGTATATTACCCAATGGAA
AATATAATGATCAGCAAAAAGACTGGATTTGCAGAAGTTTTTTTTTTTTTTTTCTTCATGCCTGATGAAAGCTTTGGCGACCCCAATATA
TGTATTTTTTGAATCTATGAACCTGAAAAGGGTCAGAAGGATGCCCAGACATCAGCCTCCTTCTTTCACCCCTTACCCCAAAGAGAAAGA
GTTTGAAACTCGAGACCATAAAGATATTCTTTAGTGGAGGCTGGATGTGCATTAGCCTGGATCCTCAGTTCTCAAATGTGTGTGGCAGCC
AGGATGACTAGATCCTGGGTTTCCATCCTTGAGATTCTGAAGTATGAAGTCTGAGGGAAACCAGAGTCTGTATTTTTCTAAACTCCCTGG
CTGTTCTGATCGGCCAGTTTTCGGAAACACTGACTTAGGTTTCAGGAAGTTGCCATGGGAAACAAATAATTTGAACTTTGGAACAGGGTT
GGCATTCAACCACGCAGGAAGCCTACTATTTAAATCCTTGGCTTCAGGTTAGTGACATTTAATGCCATCTAGCTAGCAATTGCGACCTTA
ATTTAACTTTCCAGTCTTAGCTGAGGCTGAGAAAGCTAAAGTTTGGTTTTGACAGGTTTTCCAAAAGTAAAGATGCTACTTCCCACTGTA
TGGGGGAGATTGAACTTTCCCCGTCTCCCGTCTTCTGCCTCCCACTCCATACCCCGCCAAGGAAAGGCATGTACAAAAATTATGCAATTC
AGTGTTCCAAGTCTCTGTGTAACCAGCTCAGTGTTTTGGTGGAAAAAACATTTTAAGTTTTACTGATAATTTGAGGTTAGATGGGAGGAT
GAATTGTCACATCTATCCACACTGTCAAACAGGTTGGTGTGGGTTCATTGGCATTCTTTGCAATACTGCTTAATTGCTGATACCATATGA
ATGAAACATGGGCTGTGATTACTGCAATCACTGTGCTATCGGCAGATGATGCTTTGGAAGATGCAGAAGCAATAATAAAGTACTTGACTA
CCTACTGGTGTAATCTCAATGCAAGCCCCAACTTTCTTATCCAACTTTTTCATAGTAAGTGCGAAGACTGAGCCAGATTGGCCAATTAAA
AACGAAAACCTGACTAGGTTCTGTAGAGCCAATTAGACTTGAAATACGTTTGTGTTTCTAGAATCACAGCTCAAGCATTCTGTTTATCGC
TCACTCTCCCTTGTACAGCCTTATTTTGTTGGTGCTTTGCATTTTGATATTGCTGTGAGCCTTGCATGACATCATGAGGCCGGATGAAAC
TTCTCAGTCCAGCAGTTTCCAGTCCTAACAAATGCTCCCACCTGAATTTGTATATGACTGCATTTGTGTGTGTGTGTGTGTTTTCAGCAA
ATTCCAGATTTGTTTCCTTTTGGCCTCCTGCAAAGTCTCCAGAAGAAAATTTGCCAATCTTTCCTACTTTCTATTTTTATGATGACAATC
AAAGCCGGCCTGAGAAACACTATTTGTGACTTTTTAAACGATTAGTGATGTCCTTAAAATGTGGTCTGCCAATCTGTACAAAATGGTCCT
ATTTTTGTGAAGAGGGACATAAGATAAAATGATGTTATACATCAATATGTATATATGTATTTCTATATAGACTTGGAGAATACTGCCAAA
ACATTTATGACAAGCTGTATCACTGCCTTCGTTTATATTTTTTTAACTGTGATAATCCCCACAGGCACATTAACTGTTGCACTTTTGAAT
GTCCAAAATTTATATTTTAGAAATAATAAAAAGAAAGATACTTACATGTTCCCAAAACAATGGTGTGGTGAATGTGTGAGAAAAACTAAC
TTGATAGGGTCTACCAATACAAAATGTATTACGAATGCCCCTGTTCATGTTTTTGTTTTAAAACGTGTAAATGAAGATCTTTATATTTCA

>9530_9530_1_BCR-PDGFRA_BCR_chr22_23615320_ENST00000305877_PDGFRA_chr4_55141007_ENST00000257290_length(amino acids)=1196AA_BP=656
MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEP
RASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNV
EFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPP
WPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTY
RMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQ
DGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTS
QQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDA
KDPTTKNSLETLLYKPVDRVTRSTLVLHKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAY
GLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKK
ELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLL
DLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGI
LLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSD
HPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKRE

--------------------------------------------------------------
>9530_9530_2_BCR-PDGFRA_BCR_chr22_23615320_ENST00000359540_PDGFRA_chr4_55141007_ENST00000257290_length(transcript)=7162nt_BP=2570nt
GGGGGGAGGGTGGCGGCTCGATGGGGGAGCCGCCTCCAGGGGGCCCCCCCGCCCTGTGCCCACGGCGCGGCCCCTTTAAGAGGCCCGCCT
GGCTCCGTCATCCGCGCCGCGGCCACCTCCCCCCGGCCCTCCCCTTCCTGCGGCGCAGAGTGCGGGCCGGGCGGGAGTGCGGCGAGAGCC
GGCTGGCTGAGCTTAGCGTCCGAGGAGGCGGCGGCGGCGGCGGCGGCACGGCGGCGGCGGGGCTGTGGGGCGGTGCGGAAGCGAGAGGCG
AGGAGCGCGCGGGCCGTGGCCAGAGTCTGGCGGCGGCCTGGCGGAGCGGAGAGCAGCGCCCGCGCCTCGCCGTGCGGAGGAGCCCCGCAC
ACAATAGCGGCGCGCGCAGCCCGCGCCCTTCCCCCCGGCGCGCCCCGCCCCGCGCGCCGAGCGCCCCGCTCCGCCTCACCTGCCACCAGG
GAGTGGGCGGGCATTGTTCGCCGCCGCCGCCGCCGCGCGGGCCATGGGGGCCGCCCGGCGCCCGGGGCCGGGCTGGCGAGGCGCCGCGCC
GCCGCTGAGACGGGCCCCGCGCGCAGCCCGGCGGCGCAGGTAAGGCCGGCCGCGCCATGGTGGACCCGGTGGGCTTCGCGGAGGCGTGGA
AGGCGCAGTTCCCGGACTCAGAGCCCCCGCGCATGGAGCTGCGCTCAGTGGGCGACATCGAGCAGGAGCTGGAGCGCTGCAAGGCCTCCA
TTCGGCGCCTGGAGCAGGAGGTGAACCAGGAGCGCTTCCGCATGATCTACCTGCAGACGTTGCTGGCCAAGGAAAAGAAGAGCTATGACC
GGCAGCGATGGGGCTTCCGGCGCGCGGCGCAGGCCCCCGACGGCGCCTCCGAGCCCCGAGCGTCCGCGTCGCGCCCGCAGCCAGCGCCCG
CCGACGGAGCCGACCCGCCGCCCGCCGAGGAGCCCGAGGCCCGGCCCGACGGCGAGGGTTCTCCGGGTAAGGCCAGGCCCGGGACCGCCC
GCAGGCCCGGGGCAGCCGCGTCGGGGGAACGGGACGACCGGGGACCCCCCGCCAGCGTGGCGGCGCTCAGGTCCAACTTCGAGCGGATCC
GCAAGGGCCATGGCCAGCCCGGGGCGGACGCCGAGAAGCCCTTCTACGTGAACGTCGAGTTTCACCACGAGCGCGGCCTGGTGAAGGTCA
ACGACAAAGAGGTGTCGGACCGCATCAGCTCCCTGGGCAGCCAGGCCATGCAGATGGAGCGCAAAAAGTCCCAGCACGGCGCGGGCTCGA
GCGTGGGGGATGCATCCAGGCCCCCTTACCGGGGACGCTCCTCGGAGAGCAGCTGCGGCGTCGACGGCGACTACGAGGACGCCGAGTTGA
ACCCCCGCTTCCTGAAGGACAACCTGATCGACGCCAATGGCGGTAGCAGGCCCCCTTGGCCGCCCCTGGAGTACCAGCCCTACCAGAGCA
TCTACGTCGGGGGCATGATGGAAGGGGAGGGCAAGGGCCCGCTCCTGCGCAGCCAGAGCACCTCTGAGCAGGAGAAGCGCCTTACCTGGC
CCCGCAGGTCCTACTCCCCCCGGAGTTTTGAGGATTGCGGAGGCGGCTATACCCCGGACTGCAGCTCCAATGAGAACCTCACCTCCAGCG
AGGAGGACTTCTCCTCTGGCCAGTCCAGCCGCGTGTCCCCAAGCCCCACCACCTACCGCATGTTCCGGGACAAAAGCCGCTCTCCCTCGC
AGAACTCGCAACAGTCCTTCGACAGCAGCAGTCCCCCCACGCCGCAGTGCCATAAGCGGCACCGGCACTGCCCGGTTGTCGTGTCCGAGG
CCACCATCGTGGGCGTCCGCAAGACCGGGCAGATCTGGCCCAACGATGGCGAGGGCGCCTTCCATGGAGACGCAGATGGCTCGTTCGGAA
CACCACCTGGATACGGCTGCGCTGCAGACCGGGCAGAGGAGCAGCGCCGGCACCAAGATGGGCTGCCCTACATTGATGACTCGCCCTCCT
CATCGCCCCACCTCAGCAGCAAGGGCAGGGGCAGCCGGGATGCGCTGGTCTCGGGAGCCCTGGAGTCCACTAAAGCGAGTGAGCTGGACT
TGGAAAAGGGCTTGGAGATGAGAAAATGGGTCCTGTCGGGAATCCTGGCTAGCGAGGAGACTTACCTGAGCCACCTGGAGGCACTGCTGC
TGCCCATGAAGCCTTTGAAAGCCGCTGCCACCACCTCTCAGCCGGTGCTGACGAGTCAGCAGATCGAGACCATCTTCTTCAAAGTGCCTG
AGCTCTACGAGATCCACAAGGAGTTCTATGATGGGCTCTTCCCCCGCGTGCAGCAGTGGAGCCACCAGCAGCGGGTGGGCGACCTCTTCC
AGAAGCTGGCCAGCCAGCTGGGTGTGTACCGGGCCTTCGTGGACAACTACGGAGTTGCCATGGAAATGGCTGAGAAGTGCTGTCAGGCCA
ATGCTCAGTTTGCAGAAATCTCCGAGAACCTGAGAGCCAGAAGCAACAAAGATGCCAAGGATCCAACGACCAAGAACTCTCTGGAAACTC
TGCTCTACAAGCCTGTGGACCGTGTGACGAGGAGCACGCTGGTCCTCCATAAACCGAGGTATGAAATTCGCTGGAGGGTCATTGAATCAA
TCAGCCCAGATGGACATGAATATATTTATGTGGACCCGATGCAGCTGCCTTATGACTCAAGATGGGAGTTTCCAAGAGATGGACTAGTGC
TTGGTCGGGTCTTGGGGTCTGGAGCGTTTGGGAAGGTGGTTGAAGGAACAGCCTATGGATTAAGCCGGTCCCAACCTGTCATGAAAGTTG
CAGTGAAGATGCTAAAACCCACGGCCAGATCCAGTGAAAAACAAGCTCTCATGTCTGAACTGAAGATAATGACTCACCTGGGGCCACATT
TGAACATTGTAAACTTGCTGGGAGCCTGCACCAAGTCAGGCCCCATTTACATCATCACAGAGTATTGCTTCTATGGAGATTTGGTCAACT
ATTTGCATAAGAATAGGGATAGCTTCCTGAGCCACCACCCAGAGAAGCCAAAGAAAGAGCTGGATATCTTTGGATTGAACCCTGCTGATG
AAAGCACACGGAGCTATGTTATTTTATCTTTTGAAAACAATGGTGACTACATGGACATGAAGCAGGCTGATACTACACAGTATGTCCCCA
TGCTAGAAAGGAAAGAGGTTTCTAAATATTCCGACATCCAGAGATCACTCTATGATCGTCCAGCCTCATATAAGAAGAAATCTATGTTAG
ACTCAGAAGTCAAAAACCTCCTTTCAGATGATAACTCAGAAGGCCTTACTTTATTGGATTTGTTGAGCTTCACCTATCAAGTTGCCCGAG
GAATGGAGTTTTTGGCTTCAAAAAATTGTGTCCACCGTGATCTGGCTGCTCGCAACGTCCTCCTGGCACAAGGAAAAATTGTGAAGATCT
GTGACTTTGGCCTGGCCAGAGACATCATGCATGATTCGAACTATGTGTCGAAAGGCAGTACCTTTCTGCCCGTGAAGTGGATGGCTCCTG
AGAGCATCTTTGACAACCTCTACACCACACTGAGTGATGTCTGGTCTTATGGCATTCTGCTCTGGGAGATCTTTTCCCTTGGTGGCACCC
CTTACCCCGGCATGATGGTGGATTCTACTTTCTACAATAAGATCAAGAGTGGGTACCGGATGGCCAAGCCTGACCACGCTACCAGTGAAG
TCTACGAGATCATGGTGAAATGCTGGAACAGTGAGCCGGAGAAGAGACCCTCCTTTTACCACCTGAGTGAGATTGTGGAGAATCTGCTGC
CTGGACAATATAAAAAGAGTTATGAAAAAATTCACCTGGACTTCCTGAAGAGTGACCATCCTGCTGTGGCACGCATGCGTGTGGACTCAG
ACAATGCATACATTGGTGTCACCTACAAAAACGAGGAAGACAAGCTGAAGGACTGGGAGGGTGGTCTGGATGAGCAGAGACTGAGCGCTG
ACAGTGGCTACATCATTCCTCTGCCTGACATTGACCCTGTCCCTGAGGAGGAGGACCTGGGCAAGAGGAACAGACACAGCTCGCAGACCT
CTGAAGAGAGTGCCATTGAGACGGGTTCCAGCAGTTCCACCTTCATCAAGAGAGAGGACGAGACCATTGAAGACATCGACATGATGGATG
ACATCGGCATAGACTCTTCAGACCTGGTGGAAGACAGCTTCCTGTAACTGGCGGATTCGAGGGGTTCCTTCCACTTCTGGGGCCACCTCT
GGATCCCGTTCAGAAAACCACTTTATTGCAATGCAGAGGTTGAGAGGAGGACTTGGTTGATGTTTAAAGAGAAGTTCCCAGCCAAGGGCC
TCGGGGAGCGTTCTAAATATGAATGAATGGGATATTTTGAAATGAACTTTGTCAGTGTTGCCTCTTGCAATGCCTCAGTAGCATCTCAGT
GGTGTGTGAAGTTTGGAGATAGATGGATAAGGGAATAATAGGCCACAGAAGGTGAACTTTGTGCTTCAAGGACATTGGTGAGAGTCCAAC
AGACACAATTTATACTGCGACAGAACTTCAGCATTGTAATTATGTAAATAACTCTAACCAAGGCTGTGTTTAGATTGTATTAACTATCTT
CTTTGGACTTCTGAAGAGACCACTCAATCCATCCATGTACTTCCCTCTTGAAACCTGATGTCAGCTGCTGTTGAACTTTTTAAAGAAGTG
CATGAAAAACCATTTTTGAACCTTAAAAGGTACTGGTACTATAGCATTTTGCTATCTTTTTTAGTGTTAAAGAGATAAAGAATAATAATT
AACCAACCTTGTTTAATAGATTTGGGTCATTTAGAAGCCTGACAACTCATTTTCATATTGTAATCTATGTTTATAATACTACTACTGTTA
TCAGTAATGCTAAATGTGTAATAATGTAACATGATTTCCCTCCAGAGAAAGCACAATTTAAAACAATCCTTACTAAGTAGGTGATGAGTT
TGACAGTTTTTGACATTTATATTAAATAACATGTTTCTCTATAAAGTATGGTAATAGCTTTAGTGAATTAAATTTAGTTGAGCATAGAGA
ACAAAGTAAAAGTAGTGTTGTCCAGGAAGTCAGAATTTTTAACTGTACTGAATAGGTTCCCCAATCCATCGTATTAAAAAACAATTAACT
GCCCTCTGAAATAATGGGATTAGAAACAAACAAAACTCTTAAGTCCTAAAAGTTCTCAATGTAGAGGCATAAACCTGTGCTGAACATAAC
TTCTCATGTATATTACCCAATGGAAAATATAATGATCAGCAAAAAGACTGGATTTGCAGAAGTTTTTTTTTTTTTTTTCTTCATGCCTGA
TGAAAGCTTTGGCGACCCCAATATATGTATTTTTTGAATCTATGAACCTGAAAAGGGTCAGAAGGATGCCCAGACATCAGCCTCCTTCTT
TCACCCCTTACCCCAAAGAGAAAGAGTTTGAAACTCGAGACCATAAAGATATTCTTTAGTGGAGGCTGGATGTGCATTAGCCTGGATCCT
CAGTTCTCAAATGTGTGTGGCAGCCAGGATGACTAGATCCTGGGTTTCCATCCTTGAGATTCTGAAGTATGAAGTCTGAGGGAAACCAGA
GTCTGTATTTTTCTAAACTCCCTGGCTGTTCTGATCGGCCAGTTTTCGGAAACACTGACTTAGGTTTCAGGAAGTTGCCATGGGAAACAA
ATAATTTGAACTTTGGAACAGGGTTGGCATTCAACCACGCAGGAAGCCTACTATTTAAATCCTTGGCTTCAGGTTAGTGACATTTAATGC
CATCTAGCTAGCAATTGCGACCTTAATTTAACTTTCCAGTCTTAGCTGAGGCTGAGAAAGCTAAAGTTTGGTTTTGACAGGTTTTCCAAA
AGTAAAGATGCTACTTCCCACTGTATGGGGGAGATTGAACTTTCCCCGTCTCCCGTCTTCTGCCTCCCACTCCATACCCCGCCAAGGAAA
GGCATGTACAAAAATTATGCAATTCAGTGTTCCAAGTCTCTGTGTAACCAGCTCAGTGTTTTGGTGGAAAAAACATTTTAAGTTTTACTG
ATAATTTGAGGTTAGATGGGAGGATGAATTGTCACATCTATCCACACTGTCAAACAGGTTGGTGTGGGTTCATTGGCATTCTTTGCAATA
CTGCTTAATTGCTGATACCATATGAATGAAACATGGGCTGTGATTACTGCAATCACTGTGCTATCGGCAGATGATGCTTTGGAAGATGCA
GAAGCAATAATAAAGTACTTGACTACCTACTGGTGTAATCTCAATGCAAGCCCCAACTTTCTTATCCAACTTTTTCATAGTAAGTGCGAA
GACTGAGCCAGATTGGCCAATTAAAAACGAAAACCTGACTAGGTTCTGTAGAGCCAATTAGACTTGAAATACGTTTGTGTTTCTAGAATC
ACAGCTCAAGCATTCTGTTTATCGCTCACTCTCCCTTGTACAGCCTTATTTTGTTGGTGCTTTGCATTTTGATATTGCTGTGAGCCTTGC
ATGACATCATGAGGCCGGATGAAACTTCTCAGTCCAGCAGTTTCCAGTCCTAACAAATGCTCCCACCTGAATTTGTATATGACTGCATTT
GTGTGTGTGTGTGTGTTTTCAGCAAATTCCAGATTTGTTTCCTTTTGGCCTCCTGCAAAGTCTCCAGAAGAAAATTTGCCAATCTTTCCT
ACTTTCTATTTTTATGATGACAATCAAAGCCGGCCTGAGAAACACTATTTGTGACTTTTTAAACGATTAGTGATGTCCTTAAAATGTGGT
CTGCCAATCTGTACAAAATGGTCCTATTTTTGTGAAGAGGGACATAAGATAAAATGATGTTATACATCAATATGTATATATGTATTTCTA
TATAGACTTGGAGAATACTGCCAAAACATTTATGACAAGCTGTATCACTGCCTTCGTTTATATTTTTTTAACTGTGATAATCCCCACAGG
CACATTAACTGTTGCACTTTTGAATGTCCAAAATTTATATTTTAGAAATAATAAAAAGAAAGATACTTACATGTTCCCAAAACAATGGTG
TGGTGAATGTGTGAGAAAAACTAACTTGATAGGGTCTACCAATACAAAATGTATTACGAATGCCCCTGTTCATGTTTTTGTTTTAAAACG

>9530_9530_2_BCR-PDGFRA_BCR_chr22_23615320_ENST00000359540_PDGFRA_chr4_55141007_ENST00000257290_length(amino acids)=1196AA_BP=656
MVDPVGFAEAWKAQFPDSEPPRMELRSVGDIEQELERCKASIRRLEQEVNQERFRMIYLQTLLAKEKKSYDRQRWGFRRAAQAPDGASEP
RASASRPQPAPADGADPPPAEEPEARPDGEGSPGKARPGTARRPGAAASGERDDRGPPASVAALRSNFERIRKGHGQPGADAEKPFYVNV
EFHHERGLVKVNDKEVSDRISSLGSQAMQMERKKSQHGAGSSVGDASRPPYRGRSSESSCGVDGDYEDAELNPRFLKDNLIDANGGSRPP
WPPLEYQPYQSIYVGGMMEGEGKGPLLRSQSTSEQEKRLTWPRRSYSPRSFEDCGGGYTPDCSSNENLTSSEEDFSSGQSSRVSPSPTTY
RMFRDKSRSPSQNSQQSFDSSSPPTPQCHKRHRHCPVVVSEATIVGVRKTGQIWPNDGEGAFHGDADGSFGTPPGYGCAADRAEEQRRHQ
DGLPYIDDSPSSSPHLSSKGRGSRDALVSGALESTKASELDLEKGLEMRKWVLSGILASEETYLSHLEALLLPMKPLKAAATTSQPVLTS
QQIETIFFKVPELYEIHKEFYDGLFPRVQQWSHQQRVGDLFQKLASQLGVYRAFVDNYGVAMEMAEKCCQANAQFAEISENLRARSNKDA
KDPTTKNSLETLLYKPVDRVTRSTLVLHKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAY
GLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHHPEKPKK
ELDIFGLNPADESTRSYVILSFENNGDYMDMKQADTTQYVPMLERKEVSKYSDIQRSLYDRPASYKKKSMLDSEVKNLLSDDNSEGLTLL
DLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGI
LLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSD
HPAVARMRVDSDNAYIGVTYKNEEDKLKDWEGGLDEQRLSADSGYIIPLPDIDPVPEEEDLGKRNRHSSQTSEESAIETGSSSSTFIKRE

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for BCR-PDGFRA


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for BCR-PDGFRA


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
HgeneBCRP11274DB00619ImatinibInhibitorSmall moleculeApproved
HgeneBCRP11274DB00619ImatinibInhibitorSmall moleculeApproved
HgeneBCRP11274DB00619ImatinibInhibitorSmall moleculeApproved
HgeneBCRP11274DB06616BosutinibInhibitorSmall moleculeApproved
HgeneBCRP11274DB06616BosutinibInhibitorSmall moleculeApproved
HgeneBCRP11274DB06616BosutinibInhibitorSmall moleculeApproved
HgeneBCRP11274DB01254DasatinibSmall moleculeApproved|Investigational
HgeneBCRP11274DB01254DasatinibSmall moleculeApproved|Investigational
HgeneBCRP11274DB01254DasatinibSmall moleculeApproved|Investigational
HgeneBCRP11274DB08901PonatinibInhibitorSmall moleculeApproved|Investigational
HgeneBCRP11274DB08901PonatinibInhibitorSmall moleculeApproved|Investigational
HgeneBCRP11274DB08901PonatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB00619ImatinibAntagonistSmall moleculeApproved
TgenePDGFRAP16234DB00619ImatinibAntagonistSmall moleculeApproved
TgenePDGFRAP16234DB00619ImatinibAntagonistSmall moleculeApproved
TgenePDGFRAP16234DB06589PazopanibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB06589PazopanibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB06589PazopanibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB08896RegorafenibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB08896RegorafenibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB08896RegorafenibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB09079NintedanibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB09079NintedanibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB09079NintedanibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgenePDGFRAP16234DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgenePDGFRAP16234DB10772Foreskin keratinocyte (neonatal)AgonistBiotechApproved
TgenePDGFRAP16234DB14840RipretinibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB14840RipretinibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB14840RipretinibInhibitorSmall moleculeApproved
TgenePDGFRAP16234DB00102BecaplerminBiotechApproved|Investigational
TgenePDGFRAP16234DB00102BecaplerminBiotechApproved|Investigational
TgenePDGFRAP16234DB00102BecaplerminBiotechApproved|Investigational
TgenePDGFRAP16234DB01268SunitinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB01268SunitinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB01268SunitinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB06043OlaratumabAntagonistBiotechApproved|Investigational
TgenePDGFRAP16234DB06043OlaratumabAntagonistBiotechApproved|Investigational
TgenePDGFRAP16234DB06043OlaratumabAntagonistBiotechApproved|Investigational
TgenePDGFRAP16234DB06595MidostaurinAntagonist|InhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB06595MidostaurinAntagonist|InhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB06595MidostaurinAntagonist|InhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB08901PonatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB08901PonatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB08901PonatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB09078LenvatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB09078LenvatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB09078LenvatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB12147ErdafitinibSubstrateSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB12147ErdafitinibSubstrateSmall moleculeApproved|Investigational
TgenePDGFRAP16234DB12147ErdafitinibSubstrateSmall moleculeApproved|Investigational

Top

Related Diseases for BCR-PDGFRA


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneBCRC0005586Bipolar Disorder4PSYGENET
HgeneBCRC0023473Myeloid Leukemia, Chronic3CTD_human;ORPHANET
HgeneBCRC0005699Blast Phase1CTD_human
HgeneBCRC0006413Burkitt Lymphoma1ORPHANET
HgeneBCRC0023893Liver Cirrhosis, Experimental1CTD_human
HgeneBCRC0027022Myeloproliferative disease1CTD_human
HgeneBCRC0027540Necrosis1CTD_human
HgeneBCRC0027659Neoplasms, Experimental1CTD_human
HgeneBCRC0041696Unipolar Depression1PSYGENET
HgeneBCRC1269683Major Depressive Disorder1PSYGENET
HgeneBCRC1292769Precursor B-cell lymphoblastic leukemia1ORPHANET
TgeneC0238198Gastrointestinal Stromal Tumors10CGI;CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
TgeneC3179349Gastrointestinal Stromal Sarcoma9CLINGEN;CTD_human;ORPHANET
TgeneC0346421Chronic eosinophilic leukemia4ORPHANET
TgeneC0206141Idiopathic Hypereosinophilic Syndrome3CTD_human;GENOMICS_ENGLAND
TgeneC0006413Burkitt Lymphoma2ORPHANET
TgeneC0206142Eosinophilic leukemia2CTD_human
TgeneC0206143Loeffler's Endocarditis2CTD_human
TgeneC1292769Precursor B-cell lymphoblastic leukemia2ORPHANET
TgeneC1540912Hypereosinophilic syndrome2CGI;CTD_human
TgeneC0008925Cleft Palate1CTD_human
TgeneC0015923Fetal Alcohol Syndrome1PSYGENET
TgeneC0018801Heart failure1CTD_human
TgeneC0018802Congestive heart failure1CTD_human
TgeneC0023212Left-Sided Heart Failure1CTD_human
TgeneC0023893Liver Cirrhosis, Experimental1CTD_human
TgeneC0024115Lung diseases1CTD_human
TgeneC0025149Medulloblastoma1CTD_human
TgeneC0035238Congenital abnormality of respiratory system1CTD_human
TgeneC0038219Status Dysraphicus1CTD_human
TgeneC0080178Spina Bifida1CTD_human
TgeneC0205833Medullomyoblastoma1CTD_human
TgeneC0206637Mesenchymal Chondrosarcoma1CTD_human
TgeneC0235527Heart Failure, Right-Sided1CTD_human
TgeneC0266508Rachischisis1CTD_human
TgeneC0278510Childhood Medulloblastoma1CTD_human
TgeneC0278876Adult Medulloblastoma1CTD_human
TgeneC0376634Craniofacial Abnormalities1CTD_human
TgeneC0751291Desmoplastic Medulloblastoma1CTD_human
TgeneC1275668Melanotic medulloblastoma1CTD_human
TgeneC1837218Cleft palate, isolated1CTD_human
TgeneC1959583Myocardial Failure1CTD_human
TgeneC1961112Heart Decompensation1CTD_human
TgeneC2718076Fetal Mummification1CTD_human
TgeneC2985290Fetal Alcohol Spectrum Disorders1PSYGENET
TgeneC4545381Myeloid and/or lymphoid neoplasm associated with platelet derived growth factor receptor alpha rearrangement1ORPHANET